Additionally, CXCR4 overexpression led to mammalian target of rapamycin (mTOR) activation in response to panobinostat treatment in MM cells, suggesting that mTOR pathway activation induces resistance to panobinostat. The gene discussed is MTOR; the disease is Miyoshi myopathy.